The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial
Open accessAbstract
Purpose To determine if the change in tumor apparent diffusion coefficient (ADC) at diffusion-weighted (DW) MRI is predictive of pathologic complete response (pCR) to neoadjuvant chemotherapy for breast cancer. Materials and Methods In this prospective multicenter study, 272 consecutive women with breast cancer were enrolled at 10 institutions (from August 2012 to January 2015) and were randomized to treatment with 12 weekly doses of paclitaxel (with or without an experimental agent), followed by 12 weeks of treatment with four cycles of anthracycline. Each woman underwent breast DW MRI before treatment, at early treatment (3 weeks), at midtreatment (12 weeks), and after treatment. Percentage change in tumor ADC from that before treatment (ΔADC) was measured at each time point. Performance for predicting pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and according to tumor hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) disease subtype. Results The final analysis included 242 patients with evaluable serial imaging data, with a mean age of 48 years ± 10 (standard deviation); 99 patients had HR-positive (hereafter, HR+)/HER2-negative (hereafter, HER2-) disease, 77 patients had HR-/HER2- disease, 42 patients had HR+/HER2+ disease, and 24 patients had HR-/HER2+ disease. Eighty (33%) of 242 patients experienced pCR. Overall, ΔADC was moderately predictive of pCR at midtreatment/12 weeks (AUC = 0.60; 95% confidence interval [CI]: 0.52, 0.68; P = .017) and after treatment (AUC = 0.61; 95% CI: 0.52, 0.69; P = .013). Across the four disease subtypes, midtreatment ΔADC was predictive only for HR+/HER2- tumors (AUC = 0.76; 95% CI: 0.62, 0.89; P < .001). In a test subset, a model combining tumor subtype and midtreatment ΔADC improved predictive performance (AUC = 0.72; 95% CI: 0.61, 0.83) over ΔADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032.). Conclusion After 12 weeks of therapy, change in breast tumor apparent diffusion coefficient at MRI predicts complete pathologic response to neoadjuvant chemotherapy. © RSNA, 2018 Online supplemental material is available for this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Spin Diffusion Measurements: Spin Echoes in the Presence of a Time-Dependent Field Gradient
Stejskal, E. O., & Tanner, J. E. (1965) · The Journal of Chemical Physics · doi:10.1063/1.1695690 · Cited by 8,286
Le Bihan, D., Breton, E., Lallemand, D., Grenier, P., Cabanis, E., & Laval-Jeantet, M. (1986) · Radiology · doi:10.1148/radiology.161.2.3763909 · Cited by 3,912
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Chenevert, T. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2029 · Cited by 673
Self-citationAdaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van ’t Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 554
Self-citationHylton, N. M., Blume, J. D., Bernreuter, W. K., Pisano, E. D., Rosen, M. A., Morris, E. A., Weatherall, P. T., Lehman, C. D., Newstead, G. M., Polin, S., et al. (2012) · Radiology · doi:10.1148/radiol.12110748 · Cited by 502
Self-citationAdaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 454
Self-citationDiffusion-weighted breast MRI: Clinical applications and emerging techniques
Partridge, S. C., Nissan, N., Rahbar, H., Kitsch, A. E., & Sigmund, E. E. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25479 · Cited by 340
Self-citationSharma, U., Danishad, K. K. A., Seenu, V., & Jagannathan, N. R. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1245 · Cited by 321
Cited by
Mann, R. M., Cho, N., & Moy, L. (2019) · Radiology · doi:10.1148/radiol.2019182947 · Cited by 917
On behalf of the EUSOBI international Breast Diffusion-Weighted Imaging working group, Baltzer, P., Mann, R. M., Iima, M., Sigmund, E. E., Clauser, P., Gilbert, F. J., Martincich, L., Partridge, S. C., Patterson, A., et al. (2020) · European Radiology · doi:10.1007/s00330-019-06510-3 · Cited by 437
Self-citationHuang, Y., Zhu, T., Zhang, X., Li, W., Zheng, X., Cheng, M., Ji, F., Zhang, L., Yang, C., Wu, Z., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101899 · Cited by 175
Metadata
- Authors
- Partridge, S. C., Zhang, Z., Newitt, D. C., Gibbs, J. E., Chenevert, T. L., Rosen, M. A., Bolan, P. J., Marques, H. S., Romanoff, J., Cimino, L., Joe, B. N., Umphrey, H. R., Ojeda-Fournier, H., Dogan, B., Oh, K., Abe, H., Drukteinis, J. S., Esserman, L. J., Hylton, N. M., & For the ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators
- Venue
- Radiology
- Published
- 2018-12
- Volume
- 289
- Issue
- 3
- Pages
- 618-627
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2890317046
- Cited by
- 288
- References
- 28
- FWCI
- 14.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. https://app.cochat.ai/papers/10.1148/radiol.2018180273
- The paper
- Partridge, S. C., Zhang, Z., Newitt, D. C., Gibbs, J. E., Chenevert, T. L., Rosen, M. A., Bolan, P. J., Marques, H. S., Romanoff, J., Cimino, L., Joe, B. N., Umphrey, H. R., Ojeda-Fournier, H., Dogan, B., Oh, K., Abe, H., Drukteinis, J. S., Esserman, L. J., Hylton, N. M., & For the ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. (2018). Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. https://doi.org/10.1148/radiol.2018180273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.